QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
QQQ   299.94 (-2.83%)
AAPL   116.36 (-4.17%)
MSFT   227.39 (-1.82%)
FB   255.31 (-3.39%)
GOOGL   2,007.50 (-4.27%)
TSLA   563.00 (-5.84%)
AMZN   2,951.95 (-1.62%)
NVDA   463.73 (-6.97%)
BABA   226.69 (-3.08%)
CGC   30.86 (-0.99%)
GE   14.17 (+4.19%)
MU   85.05 (-4.36%)
NIO   35.21 (-7.61%)
AMD   73.96 (-5.81%)
T   29.99 (+1.25%)
F   12.65 (+3.10%)
ACB   9.61 (+0.10%)
DIS   201.91 (+6.27%)
BA   224.03 (+0.36%)
NFLX   493.33 (-4.47%)
PFE   34.35 (-0.12%)
Log in
NYSE:HUM

Humana Competitors

$401.07
+1.68 (+0.42 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$397.53
Now: $401.07
$407.39
50-Day Range
$375.15
MA: $386.86
$414.60
52-Week Range
$208.25
Now: $401.07
$474.70
Volume1.10 million shs
Average Volume1.18 million shs
Market Capitalization$51.68 billion
P/E Ratio12.85
Dividend Yield0.63%
Beta0.86

Competitors

Humana (NYSE:HUM) Vs. ABT, LLY, NVS, PFE, MRK, and ABBV

Should you be buying HUM stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Humana, including Abbott Laboratories (ABT), Eli Lilly and (LLY), Novartis (NVS), Pfizer (PFE), Merck & Co., Inc. (MRK), and AbbVie (ABBV).

Abbott Laboratories (NYSE:ABT) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Valuation & Earnings

This table compares Abbott Laboratories and Humana's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abbott Laboratories$31.90 billion6.42$3.69 billion$3.2435.69
Humana$64.89 billion0.80$2.71 billion$17.8722.44

Abbott Laboratories has higher earnings, but lower revenue than Humana. Humana is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Abbott Laboratories has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Abbott Laboratories and Humana, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Abbott Laboratories111502.82
Humana041402.78

Abbott Laboratories presently has a consensus price target of $121.8333, suggesting a potential upside of 5.36%. Humana has a consensus price target of $462.10, suggesting a potential upside of 15.22%. Given Humana's higher possible upside, analysts plainly believe Humana is more favorable than Abbott Laboratories.

Profitability

This table compares Abbott Laboratories and Humana's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Abbott Laboratories10.50%18.19%8.29%
Humana5.58%22.74%8.82%

Dividends

Abbott Laboratories pays an annual dividend of $1.80 per share and has a dividend yield of 1.6%. Humana pays an annual dividend of $2.50 per share and has a dividend yield of 0.6%. Abbott Laboratories pays out 55.6% of its earnings in the form of a dividend. Humana pays out 14.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Abbott Laboratories has increased its dividend for 49 consecutive years and Humana has increased its dividend for 4 consecutive years. Abbott Laboratories is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider and Institutional Ownership

72.6% of Abbott Laboratories shares are held by institutional investors. Comparatively, 91.9% of Humana shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 0.4% of Humana shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Abbott Laboratories beats Humana on 9 of the 17 factors compared between the two stocks.

Eli Lilly and (NYSE:LLY) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.

Volatility & Risk

Eli Lilly and has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.

Dividends

Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.6%. Humana pays an annual dividend of $2.50 per share and has a dividend yield of 0.6%. Eli Lilly and pays out 56.3% of its earnings in the form of a dividend. Humana pays out 14.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and has increased its dividend for 1 consecutive years and Humana has increased its dividend for 4 consecutive years.

Valuation & Earnings

This table compares Eli Lilly and and Humana's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and$22.32 billion8.89$8.32 billion$6.0434.28
Humana$64.89 billion0.80$2.71 billion$17.8722.44

Eli Lilly and has higher earnings, but lower revenue than Humana. Humana is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

75.6% of Eli Lilly and shares are held by institutional investors. Comparatively, 91.9% of Humana shares are held by institutional investors. 0.1% of Eli Lilly and shares are held by insiders. Comparatively, 0.4% of Humana shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Eli Lilly and and Humana's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eli Lilly and24.01%166.45%15.18%
Humana5.58%22.74%8.82%

Analyst Ratings

This is a summary of recent ratings for Eli Lilly and and Humana, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eli Lilly and041012.80
Humana041402.78

Eli Lilly and presently has a consensus price target of $192.60, suggesting a potential downside of 6.97%. Humana has a consensus price target of $462.10, suggesting a potential upside of 15.22%. Given Humana's higher possible upside, analysts plainly believe Humana is more favorable than Eli Lilly and.

Novartis (NYSE:NVS) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Risk and Volatility

Novartis has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Dividends

Novartis pays an annual dividend of $2.20 per share and has a dividend yield of 2.6%. Humana pays an annual dividend of $2.50 per share and has a dividend yield of 0.6%. Novartis pays out 42.0% of its earnings in the form of a dividend. Humana pays out 14.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novartis has increased its dividend for 1 consecutive years and Humana has increased its dividend for 4 consecutive years.

Valuation and Earnings

This table compares Novartis and Humana's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novartis$47.50 billion4.03$11.73 billion$5.2415.98
Humana$64.89 billion0.80$2.71 billion$17.8722.44

Novartis has higher earnings, but lower revenue than Humana. Novartis is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

9.9% of Novartis shares are owned by institutional investors. Comparatively, 91.9% of Humana shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 0.4% of Humana shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Novartis and Humana's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novartis14.71%24.39%10.59%
Humana5.58%22.74%8.82%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Novartis and Humana, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novartis22602.40
Humana041402.78

Novartis presently has a consensus target price of $111.00, suggesting a potential upside of 32.57%. Humana has a consensus target price of $462.10, suggesting a potential upside of 15.22%. Given Novartis' higher possible upside, equities research analysts clearly believe Novartis is more favorable than Humana.

Summary

Humana beats Novartis on 9 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Risk and Volatility

Pfizer has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 4.5%. Humana pays an annual dividend of $2.50 per share and has a dividend yield of 0.6%. Pfizer pays out 52.9% of its earnings in the form of a dividend. Humana pays out 14.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 1 consecutive years and Humana has increased its dividend for 4 consecutive years.

Valuation and Earnings

This table compares Pfizer and Humana's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$51.75 billion3.70$16.27 billion$2.9511.64
Humana$64.89 billion0.80$2.71 billion$17.8722.44

Pfizer has higher earnings, but lower revenue than Humana. Pfizer is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.4% of Pfizer shares are owned by institutional investors. Comparatively, 91.9% of Humana shares are owned by institutional investors. 0.1% of Pfizer shares are owned by insiders. Comparatively, 0.4% of Humana shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Pfizer and Humana's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer17.85%24.88%9.32%
Humana5.58%22.74%8.82%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Pfizer and Humana, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer010402.29
Humana041402.78

Pfizer presently has a consensus target price of $39.5333, suggesting a potential upside of 15.09%. Humana has a consensus target price of $462.10, suggesting a potential upside of 15.22%. Given Humana's stronger consensus rating and higher possible upside, analysts clearly believe Humana is more favorable than Pfizer.

Summary

Humana beats Pfizer on 10 of the 17 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Risk and Volatility

Merck & Co., Inc. has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Dividends

Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.5%. Humana pays an annual dividend of $2.50 per share and has a dividend yield of 0.6%. Merck & Co., Inc. pays out 50.1% of its earnings in the form of a dividend. Humana pays out 14.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Merck & Co., Inc. has increased its dividend for 1 consecutive years and Humana has increased its dividend for 4 consecutive years.

Valuation and Earnings

This table compares Merck & Co., Inc. and Humana's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.01$9.84 billion$5.1914.29
Humana$64.89 billion0.80$2.71 billion$17.8722.44

Merck & Co., Inc. has higher earnings, but lower revenue than Humana. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

72.9% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 91.9% of Humana shares are owned by institutional investors. 0.3% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 0.4% of Humana shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Merck & Co., Inc. and Humana's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.24.33%53.83%16.83%
Humana5.58%22.74%8.82%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Merck & Co., Inc. and Humana, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021302.87
Humana041402.78

Merck & Co., Inc. presently has a consensus target price of $95.3571, suggesting a potential upside of 28.57%. Humana has a consensus target price of $462.10, suggesting a potential upside of 15.22%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, equities research analysts clearly believe Merck & Co., Inc. is more favorable than Humana.

Summary

Merck & Co., Inc. beats Humana on 9 of the 17 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Humana (NYSE:HUM) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership.

Risk and Volatility

AbbVie has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Humana has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500.

Insider and Institutional Ownership

67.5% of AbbVie shares are owned by institutional investors. Comparatively, 91.9% of Humana shares are owned by institutional investors. 0.1% of AbbVie shares are owned by insiders. Comparatively, 0.4% of Humana shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares AbbVie and Humana's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie18.16%439.24%13.22%
Humana5.58%22.74%8.82%

Dividends

AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.9%. Humana pays an annual dividend of $2.50 per share and has a dividend yield of 0.6%. AbbVie pays out 58.2% of its earnings in the form of a dividend. Humana pays out 14.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. AbbVie has increased its dividend for 49 consecutive years and Humana has increased its dividend for 4 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for AbbVie and Humana, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie131402.72
Humana041402.78

AbbVie presently has a consensus target price of $115.50, suggesting a potential upside of 8.85%. Humana has a consensus target price of $462.10, suggesting a potential upside of 15.22%. Given Humana's stronger consensus rating and higher possible upside, analysts clearly believe Humana is more favorable than AbbVie.

Valuation and Earnings

This table compares AbbVie and Humana's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion5.63$7.88 billion$8.9411.87
Humana$64.89 billion0.80$2.71 billion$17.8722.44

AbbVie has higher earnings, but lower revenue than Humana. AbbVie is trading at a lower price-to-earnings ratio than Humana, indicating that it is currently the more affordable of the two stocks.


Humana Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.6$115.63+1.4%$204.84 billion$31.90 billion61.18Insider Selling
Eli Lilly and logo
LLY
Eli Lilly and
2.1$207.03+0.1%$198.42 billion$22.32 billion33.83
Novartis logo
NVS
Novartis
2.1$83.73+0.3%$191.63 billion$47.50 billion27.10
Pfizer logo
PFE
Pfizer
2.6$34.35+0.1%$191.59 billion$51.75 billion22.16
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$74.17+1.4%$187.67 billion$46.84 billion16.41
AbbVie logo
ABBV
AbbVie
2.8$106.11+0.6%$187.38 billion$33.27 billion22.43
Thermo Fisher Scientific logo
TMO
Thermo Fisher Scientific
2.3$439.85+1.6%$173.21 billion$25.54 billion36.05Analyst Report
Novo Nordisk A/S logo
NVO
Novo Nordisk A/S
1.3$68.83+1.1%$162.08 billion$18.30 billion25.88
Medtronic logo
MDT
Medtronic
2.7$116.67+1.4%$157.04 billion$28.91 billion44.53Dividend Announcement
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$60.45+0.0%$135.44 billion$26.15 billion-549.50Dividend Announcement
Amgen logo
AMGN
Amgen
2.5$227.81+0.0%$131.58 billion$23.36 billion18.37Dividend Announcement
Analyst Report
Analyst Revision
AstraZeneca logo
AZN
AstraZeneca
2.1$48.19+0.3%$126.48 billion$24.38 billion50.20Analyst Report
Analyst Revision
Sanofi logo
SNY
Sanofi
1.6$46.59+0.0%$117.31 billion$40.00 billion19.91
Stryker logo
SYK
Stryker
2.0$236.00+1.7%$88.78 billion$14.88 billion51.19
GlaxoSmithKline logo
GSK
GlaxoSmithKline
1.1$34.97+0.2%$87.72 billion$43.10 billion10.76Increase in Short Interest
Anthem logo
ANTM
Anthem
2.4$339.59+1.8%$83.17 billion$104.21 billion17.56Insider Selling
Gilead Sciences logo
GILD
Gilead Sciences
2.8$64.75+0.2%$81.36 billion$22.45 billion66.75
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.7$684.90+4.2%$80.63 billion$4.48 billion78.01
Becton, Dickinson and logo
BDX
Becton, Dickinson and
2.4$246.10+0.1%$71.51 billion$17.12 billion90.15
Zoetis logo
ZTS
Zoetis
2.4$145.15+0.4%$68.97 billion$6.26 billion43.07Analyst Upgrade
HCA Healthcare logo
HCA
HCA Healthcare
2.3$189.21+2.9%$64.32 billion$51.34 billion19.13Increase in Short Interest
Takeda Pharmaceutical logo
TAK
Takeda Pharmaceutical
2.0$18.10+3.5%$57.06 billion$30.20 billion60.34Gap Down
Boston Scientific logo
BSX
Boston Scientific
2.0$39.52+0.1%$56.01 billion$10.74 billion15.14Increase in Short Interest
Analyst Revision
Illumina logo
ILMN
Illumina
1.6$383.62+4.0%$55.97 billion$3.54 billion89.01Analyst Report
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$213.58+0.7%$55.52 billion$4.16 billion26.97
Edwards Lifesciences logo
EW
Edwards Lifesciences
1.8$80.32+1.7%$50.16 billion$4.35 billion64.26Increase in Short Interest
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$463.19+0.3%$49.62 billion$7.86 billion16.93
Moderna logo
MRNA
Moderna
1.8$123.47+7.1%$49.36 billion$60.21 million-76.22Analyst Report
Insider Selling
Decrease in Short Interest
Gap Up
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.5$482.60+3.5%$41.23 billion$2.41 billion84.08
Biogen logo
BIIB
Biogen
1.9$270.01+0.3%$41.13 billion$14.38 billion8.94
Baxter International logo
BAX
Baxter International
2.3$78.28+0.3%$39.54 billion$11.36 billion44.48News Coverage
Align Technology logo
ALGN
Align Technology
2.0$496.07+8.1%$39.26 billion$2.41 billion22.57
Centene logo
CNC
Centene
2.1$61.72+1.9%$35.90 billion$74.64 billion17.19
DexCom logo
DXCM
DexCom
1.9$352.06+3.4%$33.86 billion$1.48 billion145.48
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.9$150.06+0.0%$32.99 billion$4.99 billion35.06
Alcon logo
ALC
Alcon
1.3$67.07+1.3%$32.74 billion$7.51 billion-45.63Analyst Report
Decrease in Short Interest
Zimmer Biomet logo
ZBH
Zimmer Biomet
2.1$156.50+1.3%$32.53 billion$7.98 billion978.19Analyst Report
McKesson logo
MCK
McKesson
2.2$176.09+0.6%$28.03 billion$231.05 billion13.40
Teladoc Health logo
TDOC
Teladoc Health
1.7$176.65+7.4%$26.97 billion$553.31 million-123.53
BeiGene logo
BGNE
BeiGene
1.3$294.70+2.2%$26.96 billion$428.21 million-14.58Analyst Report
Seagen logo
SGEN
Seagen
1.7$148.68+0.5%$26.94 billion$916.71 million58.54Insider Selling
Decrease in Short Interest
ResMed logo
RMD
ResMed
1.4$179.46+3.1%$26.11 billion$2.96 billion38.51
Laboratory Co. of America logo
LH
Laboratory Co. of America
1.6$240.57+1.2%$23.48 billion$11.55 billion28.01
AmerisourceBergen logo
ABC
AmerisourceBergen
2.1$107.51+2.5%$22.01 billion$189.89 billion-6.40Insider Selling
Decrease in Short Interest
BioNTech logo
BNTX
BioNTech
1.1$90.29+6.5%$21.74 billion$121.63 million-45.15Decrease in Short Interest
Cerner logo
CERN
Cerner
2.9$70.17+0.3%$21.49 billion$5.69 billion27.41
Genmab A/S logo
GMAB
Genmab A/S
1.7$31.24+1.6%$20.48 billion$804.57 million24.22High Trading Volume
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.9$34.70+0.3%$20.32 billion$19.58 billion13.77Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$116.57+4.3%$19.71 billion$876.29 million-52.75Insider Selling
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$86.77+2.2%$19.44 billion$1.30 billion23.71
This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.